In vivo functional screening via CRISPR-Cas9 to systematically identify cardiomyocyte receptors as targets for the innovative therapies for myocardial infarction and heart failure

Project Information

R-FunSel

Grant agreement ID: 842742

DOI

10.3030/842742

Project closed

EC signature date 19 March 2019

Start date 1 April 2019

End date 31 March 2021

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost

€ 212 933,76

EU contribution

€ 212 933,76

Coordinated by

KING'S COLLEGE LONDON
United Kingdom

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (1)

Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia

Author(s): Braga, L., Ali, H., Secco, I., Chiavacci, E., Neves, G., Goldhill, D., Penn, R., Jimenez-Guardeno, J.M., Ortega-Prieto, A.M., Bussani, R., Cannata, A., Rizzari, G., Collesi, C., Schneider, E., Arosio, D., Shah, A.M., Barclay, W.S., Malim, M.H., Burrone, J., Giacca, M.
Published in: Nature, 2021, Page(s) In press, 3rd June 2021, ISSN 0028-0836
Publisher: Nature Publishing Group